Organogenesis CAO discloses initial share holdings

Organogenesis Holdings Inc. filed an initial ownership statement for Chief Accounting Officer Patrick McGuire, detailing his direct holdings of Class A common stock and related equity awards.

Rhea-AI Filing Summary

Organogenesis Holdings Inc. filed an initial ownership statement for Chief Accounting Officer Patrick McGuire, detailing his direct holdings of Class A common stock and related equity awards. The filing notes that some positions represent restricted stock units granted under the 2018 Equity Incentive Plan, with unvested RSUs scheduled to vest in equal annual installments on December 29, 2026, 2027 and 2028, and on February 15, 2027, 2028 and 2029.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider McGuire Patrick

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 54,611 shares (Direct)

Footnotes (4)

1. F1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.
2. F2. Represents shares of Class A Common Stock of Organogenesis pursuant to vested RSUs under the 2018 Equity Incentive Plan.
3. F3. Represents unvested RSUs which will vest in equal annual installments on December 29, 2026, December 29, 2027, and December 29, 2028.
4. F4. Represents unvested RSUs which will vest in equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Organogenesis (ORGO) Form 3 filing for Patrick McGuire show?

The Form 3 shows Chief Accounting Officer Patrick McGuire’s initial beneficial ownership in Organogenesis Class A common stock and related equity awards. It lists direct holdings and explains that some positions are restricted stock units granted under the 2018 Equity Incentive Plan with future vesting dates.

Who is the insider reporting ownership in Organogenesis (ORGO) on this Form 3?

The insider is Patrick McGuire, Chief Accounting Officer of Organogenesis Holdings Inc. The filing classifies him as an officer and details his direct ownership of Class A common stock and restricted stock units granted under the company’s 2018 Equity Incentive Plan.

What type of securities are reported in Patrick McGuire’s Organogenesis (ORGO) Form 3?

The filing reports holdings of Organogenesis Class A common stock, including shares related to restricted stock units. Footnotes explain that each RSU represents a contingent right to receive one share of Class A common stock upon vesting under the 2018 Equity Incentive Plan.

How are restricted stock units described in the Organogenesis (ORGO) Form 3?

Restricted stock units are described as grants under the Organogenesis 2018 Equity Incentive Plan. Each RSU gives a contingent right to receive one Class A common share upon vesting, with specific grants vesting in equal annual installments from December 29, 2026 through 2028 and February 15, 2027 through 2029.

When will Patrick McGuire’s unvested Organogenesis (ORGO) RSUs vest?

Unvested RSUs are scheduled to vest in equal annual installments on December 29, 2026, 2027 and 2028, and on February 15, 2027, 2028 and 2029. These vesting schedules apply to restricted stock unit grants made under the Organogenesis 2018 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/27/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

McGuire Patrick

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/18/2026

3. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Common Stock	9,521(2)	D
Class A Common Stock(1)	16,965(3)	D
Class A Common Stock(1)	28,125(4)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.

2. Represents shares of Class A Common Stock of Organogenesis pursuant to vested RSUs under the 2018 Equity Incentive Plan.

3. Represents unvested RSUs which will vest in equal annual installments on December 29, 2026, December 29, 2027, and December 29, 2028.

4. Represents unvested RSUs which will vest in equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029.

Remarks:

Exhibit 24 Power of Attorney filed herewith.

	/s/ William R. Kolb, Attorney-in-Fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.